Inhibikase Therapeutics expanding therapeutic pipeline for Parkinson's and related disorders.

From Globe Newswire: 2024-06-05 08:05:00

Inhibikase Therapeutics, Inc. announced expansion of its therapeutic pipeline for Parkinson’s disease and related disorders. Dr. Milton H. Werner stated the 201 Trial for untreated Parkinson’s disease is 94% enrolled, with the last patient expected mid-June. The company is seeking grant funding for a trial in Multiple System Atrophy and redirecting efforts into cardiopulmonary disease with IkT-001Pro. Other milestones include scaling manufacturing for IkT-001Pro and discontinuing antiviral development for Progressive Multifocal Leukoencephalopathy. Upcoming plans include completing the 201 Trial and expanding into cardiopulmonary disease.

For more information about Inhibikase Therapeutics, visit www.inhibikase.com. For investors, the company uses various platforms like X, Facebook, LinkedIn, and YouTube for disclosure. This press release contains forward-looking statements based on current expectations, subject to risks and uncertainties. Contacts for the company include President & CEO, Milton H. Werner, and Investor Relations, Alex Lobo from Precision AQ.



Read more at Globe Newswire: Inhibikase Therapeutics Announces Expansion to its